CH563339A5 - - Google Patents

Info

Publication number
CH563339A5
CH563339A5 CH177974A CH177974A CH563339A5 CH 563339 A5 CH563339 A5 CH 563339A5 CH 177974 A CH177974 A CH 177974A CH 177974 A CH177974 A CH 177974A CH 563339 A5 CH563339 A5 CH 563339A5
Authority
CH
Switzerland
Application number
CH177974A
Original Assignee
Pharmastra Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20259298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH563339(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmastra Ag filed Critical Pharmastra Ag
Publication of CH563339A5 publication Critical patent/CH563339A5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
CH177974A 1970-02-18 1971-02-16 CH563339A5 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE02050/70A SE354851B (sv) 1970-02-18 1970-02-18

Publications (1)

Publication Number Publication Date
CH563339A5 true CH563339A5 (sv) 1975-06-30

Family

ID=20259298

Family Applications (8)

Application Number Title Priority Date Filing Date
CH221671A CH563338A5 (sv) 1970-02-18 1971-02-16
CH278675A CH572895A5 (sv) 1970-02-18 1971-02-16
CH178074A CH563340A5 (sv) 1970-02-18 1971-02-16
CH177974A CH563339A5 (sv) 1970-02-18 1971-02-16
CH278575A CH578507A5 (sv) 1970-02-18 1971-02-16
CH278875A CH572897A5 (sv) 1970-02-18 1971-02-16
CH278975A CH576938A5 (sv) 1970-02-18 1971-02-16
CH278775A CH572896A5 (sv) 1970-02-18 1971-02-16

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CH221671A CH563338A5 (sv) 1970-02-18 1971-02-16
CH278675A CH572895A5 (sv) 1970-02-18 1971-02-16
CH178074A CH563340A5 (sv) 1970-02-18 1971-02-16

Family Applications After (4)

Application Number Title Priority Date Filing Date
CH278575A CH578507A5 (sv) 1970-02-18 1971-02-16
CH278875A CH572897A5 (sv) 1970-02-18 1971-02-16
CH278975A CH576938A5 (sv) 1970-02-18 1971-02-16
CH278775A CH572896A5 (sv) 1970-02-18 1971-02-16

Country Status (17)

Country Link
US (4) US3873600A (sv)
JP (2) JPS5317587B1 (sv)
AT (3) AT310144B (sv)
BE (1) BE762629A (sv)
CA (1) CA982140A (sv)
CH (8) CH563338A5 (sv)
DE (1) DE2106209C3 (sv)
DK (1) DK129446B (sv)
FI (1) FI55024C (sv)
FR (1) FR2081523B1 (sv)
GB (1) GB1308106A (sv)
IE (1) IE35106B1 (sv)
MY (1) MY7500161A (sv)
NL (1) NL160549C (sv)
NO (1) NO132798C (sv)
SE (1) SE354851B (sv)
ZA (1) ZA71682B (sv)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE384853B (sv) * 1972-04-04 1976-05-24 Haessle Ab Forfarande for framstellning av nya aminer
US4145442A (en) * 1972-04-04 1979-03-20 Aktiebolaget Hassle Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
US4035420A (en) * 1972-07-06 1977-07-12 Aktiebolaget Hassle Substituted ureido alkylene phenoxy propanolamines
US4041075A (en) * 1973-12-12 1977-08-09 Imperial Chemical Industries Limited Phenoxy-alkanolamine derivatives
AT334385B (de) * 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
SE7402096L (sv) * 1974-02-18 1975-08-19 United Aircraft Corp
US4145363A (en) * 1975-02-05 1979-03-20 Yamanouchi Pharmaceutical Co., Ltd. 4-Carbamoylamino-α-aminomethylbenzyl alcohol derivatives
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
IT1109002B (it) * 1977-09-22 1985-12-16 Menarini Sas Derivati del 2 oxazolidone e loro metodi di preparazione
US4243681A (en) * 1977-10-11 1981-01-06 Mead Johnson & Company Alkylthiophenoxypropanolamines and pharmaceutical compositions and uses thereof
US4341718A (en) * 1978-07-03 1982-07-27 American Home Products Corporation α-[(Alkylamino)-methyl]-β-aryloxy-benzeneethanols exhibiting antiarrhythmic activity
US4329502A (en) * 1978-08-28 1982-05-11 Syva Company Propranolol antigen conjugates and antibodies
FR2477537A1 (fr) * 1980-03-07 1981-09-11 Francaise Sucrerie Nouvelles guanidines acylees, urees et urees substituees, leur procede de fabrication et leur application en tant que medicaments
FI59985C (fi) * 1980-05-26 1982-01-08 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiv 1-isopropylamino-3-(4-(2-metoxietyl)fenoxi)-2-propanol samt dess syra-additionssalter
SE8004087L (sv) * 1980-06-02 1981-12-03 Haessle Ab Nya parasubstituerade 3-fenoxi-1-alkylaminopropanol-2-er med betareceptorblockerande egenskaper, samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma, och metod att behandla akut ...
SE8004088L (sv) * 1980-06-02 1981-12-03 Haessle Ab Nya substituerade 3-fenoxi-l-alkoxikarbonylalkylamino-propanol-2-er med beta-receptorblockerande egenskaper samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma och metod att ...
FI63016C (fi) * 1980-06-04 1983-04-11 Haessle Ab Foerfarande foer framstaellning av en terapeutiskt aktiv propanolamin
US4342783A (en) * 1980-06-30 1982-08-03 Synthelabo Anti-glaucoma agent
FR2497194B1 (fr) * 1980-08-07 1985-06-14 Sandoz Sa Nouveaux composes phenoliques
CH643527A5 (en) * 1980-10-24 1984-06-15 Ciba Geigy Ag Process for the preparation of 1-alkylamino-3-(4-(2-lower alkoxy-ethyl)phenoxy)-2-propanols
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte
US4450172A (en) * 1982-03-10 1984-05-22 E. I. Du Pont De Nemours And Company Antihypertensive polyhalohydroxyisopropyl phenylalka(e)noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
DE3210061A1 (de) * 1982-03-19 1983-09-22 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von propafenon
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US5081154A (en) * 1984-01-10 1992-01-14 Aktiebolaget Hassle Metoprolol succinate
FR2568249B1 (fr) * 1984-07-25 1986-12-05 Lipha Amino-1 aryloxy-3 propanols-2, procedes de preparation et medicaments les contenant
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
WO1988000190A1 (en) * 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
JPS6388944U (sv) * 1986-12-01 1988-06-09
JPS6445265A (en) * 1987-08-06 1989-02-17 Kotobukiya Goushi Lidded box having socket and spigot part and its manufacture
ES2011584A6 (es) * 1989-05-26 1990-01-16 Esteve Quimica Sa Procedimiento industrial para la obtencion de una ariloxipropanolamina.
GB8925032D0 (en) * 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5107034A (en) * 1990-03-28 1992-04-21 Hoechst Celanese Corporation Method for producing 4-(2'-methoxyethyl)phenol
ES2065291B1 (es) * 1993-07-30 1995-10-01 Prodesfarma Sa "nitrato esteres de 1-ariloxi-3-alquilamino-2-propanoles, utilizacion y composicion farmaceutica correspondiente"
US5859390A (en) * 1996-10-23 1999-01-12 Hill-Rom, Inc. Hospital bed scale mounting apparatus
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
KR100469946B1 (ko) * 1998-04-14 2005-05-17 삼성정밀화학 주식회사 키랄(s)-2,3-치환-1-프로필아민유도체의제조방법
KR100469947B1 (ko) * 1998-04-14 2005-04-08 삼성정밀화학 주식회사 키랄(s)-3-아미노-1,2-프로판디올의제조방법
KR100489649B1 (ko) * 1998-04-14 2005-09-02 삼성정밀화학 주식회사 (s)-3-치환-2-히드록시프로필아민의제조방법
US6924441B1 (en) 1999-09-29 2005-08-02 Hill-Rom Services, Inc. Load cell apparatus
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7176391B2 (en) * 2004-09-13 2007-02-13 Hill-Rom Services, Inc. Load cell to frame interface for hospital bed
KR20080016527A (ko) * 2005-01-31 2008-02-21 밀란 래보러토리즈, 인크. 하이드록시화된 네비볼롤을 함유하는 약학적 조성물
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
CN102381995B (zh) * 2010-08-31 2015-04-15 扬子江药业集团北京海燕药业有限公司 美托洛尔的制备方法
CN102295569B (zh) * 2011-07-04 2014-05-21 南京工业大学 一种制备(s)-琥珀酸美托洛尔的方法
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP7128969B2 (ja) 2019-01-18 2022-08-31 アストラゼネカ・アクチエボラーグ Ｐｃｓｋ９阻害剤及びその使用方法
CN112645827A (zh) * 2020-12-25 2021-04-13 浙江普洛家园药业有限公司 一种连续合成美多心安及其盐的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) * 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
GB1199037A (en) * 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
US3466325A (en) * 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
US3637827A (en) * 1966-01-06 1972-01-25 Smith Kline French Lab Benzhydryloxy-cyclopropanecarboxylic acids and amides
US3541130A (en) * 1967-02-06 1970-11-17 Boehringer Sohn Ingelheim 1-(cyanophenoxy)-2-hydroxy-3-tert.-butylamine propanes
DE1937477C3 (de) * 1969-07-23 1980-04-10 C.H. Boehringer Sohn, 6507 Ingelheim I -Phenoxy-2-hydroxy-3-(l -methylcycloalkylamino)-propane, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
JPS5247447A (en) * 1975-09-29 1977-04-15 Touhoku Nougiyou Shikenjiyouch Blue film utilizing method for growing of paddy rice young plant

Also Published As

Publication number Publication date
CH563340A5 (sv) 1975-06-30
JPS5755710B2 (sv) 1982-11-25
DE2106209A1 (de) 1971-08-26
FR2081523B1 (sv) 1974-08-02
GB1308106A (en) 1973-02-28
US3928601A (en) 1975-12-23
ZA71682B (en) 1971-10-27
MY7500161A (en) 1975-12-31
FI55024C (fi) 1979-05-10
CH578507A5 (sv) 1976-08-13
CH572896A5 (sv) 1976-02-27
CH563338A5 (sv) 1975-06-30
BE762629A (fr) 1971-08-09
IE35106B1 (en) 1975-11-12
US3876802A (en) 1975-04-08
NL7101885A (sv) 1971-08-20
CH572897A5 (sv) 1976-02-27
FR2081523A1 (sv) 1971-12-03
US3873600A (en) 1975-03-25
CH576938A5 (sv) 1976-06-30
DE2106209B2 (de) 1979-08-30
JPS53101322A (en) 1978-09-04
US3998790A (en) 1976-12-21
AT317181B (de) 1974-08-12
IE35106L (en) 1971-08-18
DK129446B (da) 1974-10-14
CA982140A (en) 1976-01-20
DK129446C (sv) 1975-03-03
JPS5317587B1 (sv) 1978-06-09
NL160549B (nl) 1979-06-15
SE354851B (sv) 1973-03-26
AT310144B (de) 1973-09-25
DE2106209C3 (de) 1980-05-29
NL160549C (nl) 1979-11-15
AT307386B (de) 1973-05-25
CH572895A5 (sv) 1976-02-27
FI55024B (fi) 1979-01-31
NO132798B (sv) 1975-09-29
NO132798C (sv) 1976-01-07

Similar Documents

Publication Publication Date Title
ATA96471A (sv)
AU1146470A (sv)
AU2044470A (sv)
AU1473870A (sv)
AU1326870A (sv)
AU2130570A (sv)
AU2085370A (sv)
AU2017870A (sv)
AU1833270A (sv)
AU1716970A (sv)
AU1517670A (sv)
AU1336970A (sv)
AU1591370A (sv)
AU1064870A (sv)
AU2144270A (sv)
AU2131570A (sv)
AU2130770A (sv)
AU1328670A (sv)
AU1277070A (sv)
AU1343870A (sv)
AU1247570A (sv)
ATA672271A (sv)
AU2119370A (sv)
AU1581370A (sv)
AU1235770A (sv)

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: ASTRA PHARMACEUTICA AG

PL Patent ceased